lilly tirzepatide approval FDA for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly lowers self-pay prices of

Severity and Discontinuation 13 events were mild 7 events were moderate 1 event was severe and serious Two discontinuations, both in the 12 mg group: One due to QT interval prolongation One due to moderate palpitations Types of Reported Arrhythmia-Related Events (Frequency varies by dose

compared the impact of single versus combined treatment with high-intensity interval exercise (HIIE) and GLP-1RA semaglutide on cognitive dysfunction in obese diabetic mice ( Altogether, these converging findings highlight the hybrid potential of exercise, GLP-1based therapies, and neuromodulation to optimize weight management, cognitive function, and metabolic health

This is where the concept of synergy comes in

In individuals with type 2 diabetes and a heightened risk of cardiovascular events, tirzepatide demonstrated greater and clinically significant reduction in HbA1c compared to glargine at week 52

Ozempic (semaglutide) is widely available through pharmacies with a prescription from your healthcare provider